Navigation Links
Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

a experienced a 20 percent tumor reduction. Lastly, a patient with NK/T cell lymphoma had a 75 percent reduction in tumor measurements. Adverse events included two Grade 3 dose- limiting toxicities (upper respiratory infection (URI) and elevated liver enzymes) and five cases of Grade 3 thrombocytopenia (low-platelet count) without any sign of bleeding.

Reductions in platelet counts were analyzed in the three ongoing Phase I trials as a biomarker of Bcl-2 family protein inhibition. Subjects received doses ranging from 10 mg to 315 mg. The study data demonstrate that ABT-263 induces a transient decrease in circulating platelets via inhibition of Bcl- XL, without decreasing platelet production, confirming on-target activity. At 315 mg, researchers observed a 69 percent reduction in mean platelets from baseline values. Typically, platelet nadir occurred on days three to five with recovery during continued dosing. Tumor regression was observed in six patients, with three patients showing more than 50 percent tumor shrinkage. Adverse events included three dose-limiting toxicities, one Grade 3 URI at 160 mg, one Grade 3 alanine aminotransferase (ALT) elevation at 315 mg and one fatal respiratory failure at 10 mg. Updated information will be presented at the ASCO Annual Meeting.

ABT-869

Twenty-four patients from a completed Phase I trial (ABT-869), which studied three dose levels of ABT-869, were evaluated to compare two different measures of angiogenesis using functional imaging -- the distributed parameter (DP) model and the transfer constant (Ktrans) model. DP is a dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) model that enables derivation of blood flow and capillary permeability-surface area product (PS). Tests indicated that time over threshold could be an important predictor of efficacy, and results demonstrated that an appropriate value for the plasma concentration threshold could be 0.08 ug/mL, with time above threshold value of
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott to Present at Citi Investment Research Global Health Care Conference
2. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
4. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
5. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
6. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
7. Abbott Hosts Conference Call for First-Quarter Earnings
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
10. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
11. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... School of Medicine (BUSM) have discovered that the ... experimental model. The findings, reported in the ... may lead to more effective treatments for alcoholism. ... the leading causes of illness and death in ... by limiting the productivity of workers and necessitating ...
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... , SUNDAY, Dec. 26 (HealthDay News) -- How do ... living human being and not a replica such as a doll ... they are crucial to helping people distinguish real faces from those ... face and knowing that the lights are on and someone is ...
... FRIDAY, Dec. 24 (HealthDay News) -- The lack of sleep ... put their health at risk, British sleep experts suggest. ... harm Santa,s long-term health, there are short-term risks, according to ... of Warwick,s Warwick Medical School. The lack of sleep ...
... , THURSDAY, Dec. 23 (HealthDay News) -- Eating ... toxic phosphorus in the blood and urine, says a small ... intake of phosphorous -- which is found in dietary proteins ... have difficulty ridding themselves of the mineral. In these patients, ...
... activated in cancers, causes internal membranes within a healthy ... degrading proteins, preventing the enzyme from doing its job ... cell, researchers at UCLA,s Jonsson Comprehensive Cancer Center have ... enzyme, Glycogen Synthase Kinase 3 (GSK3), results in the ...
... Reporter , WEDNESDAY, Dec. 22 (HealthDay News) -- Confronting ... who are unaware they are taking dummy pills, researchers ... was fake still reported significant symptom relief. In ... (IBS), a control group received no treatment while the ...
... THURSDAY, Dec. 23 (HealthDay News) -- Liz Smith has six kids, ... of arthritis in Emily, now 18, appeared when she was just ... slipped in a swimming pool and had a swollen ankle that ... all of it." For several months, the family agonized over ...
Cached Medicine News:Health News:Could Santa's Lack of Sleep on Christmas Eve Harm His Health? 2Health News:Vegetarian Diet Cuts Kidney Patients' Levels of Toxic Phosphorus 2Health News:UCLA researchers uncover new cell biological mechanism that regulates protein stability in cells 2Health News:Placebos Work -- Even if Patients Are in on the Secret 2Health News:Placebos Work -- Even if Patients Are in on the Secret 3Health News:Lifetime of Arthritis Has Not Held Back Teen 2Health News:Lifetime of Arthritis Has Not Held Back Teen 3
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Investment in Vaccine to Prevent Rotavirus, NEW ... that it has purchased a royalty interest in ... an oral,vaccine developed to prevent rotavirus infection, a ... infants and young children.,The product is marketed by ...
... The Public Patent,Foundation ("PUBPAT") announced today that the U.S. ... patents held by Gilead Sciences,that relate to the drug ... in the battle against HIV/AIDS. Gilead markets TDF in,the ... a part of its ATRIPLA,combination product., Roughly 40 ...
Cached Medicine Technology:Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKline's Rotarix(R) 2U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences' Claims 2
The Guidant INSIGNIA Ultra pacing system offers sophisticated patient-specific, easy-to-use features for simplified patient management and enhanced patient safety....
... fast, the HI VISION 8500 diagnostic ... with user-oriented operation for exceptional imaging ... package consists of advanced techniques for ... COMPOUND multi-angle spatial compounding, wideband pulse-inversion, ...
... range of diagnosis by using the Convex Scanning ... clear image of blood flow by using the ... accessory elevator has been incorporated and the balloon ... for more advanced and accurate techniques. The FG-36UX ...
... system is an expanded menu profiler designed ... much as 50 percent and deliver faster ... the AccuSense® glucose oxygen sensor, enhanced data ... the CX9 ALX system offers general and ...
Medicine Products: